US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

CERo Therapeutics Holdings, Inc.

9.46

+0.23002.49%

Post-market: 9.36-0.1000-1.06%19:59 EDT

Volume:90.89K

Turnover:858.13K

Market Cap:4.88M

PE:0.00

High:9.73

Open:9.10

Low:9.10

Close:9.23

Loading ...

Overview Company News Filings

Cero Therapeutics Holdings Inc. Completes Additional Closings, Issuing 938 and 2,315 Shares of Series D Preferred Stock for $750,400 and $1,852,000 Respectively

CERo Therapeutics Raised to Buy From Hold by D. Boral Capital

Cero Therapeutics Announces No Dose-Limiting Toxicities in First Patient of Phase 1 Trial for Novel Cancer Therapy CER-1236

Cero Therapeutics Holdings, Inc. Announces First Patient Completes Dose-Limiting Toxicity Observation Period With No Reported Dlts in Phase 1 Trial of Cer-1236

THOMSON REUTERS

Top Premarket Decliners

MT Newswires Live

Top Midday Gainers

MT Newswires Live

CERo Therapeutics Holdings Inc trading halted, volatility trading pause

Cero Therapeutics Holdings Inc. Receives FDA Orphan Drug Designation for CER-1236 in Acute Myeloid Leukemia Treatment

Cero Therapeutics Holdings, Inc. Announces FDA Orphan Drug Designation Granted to Cer-1236 for the Treatment of Acute Myeloid Leukemia (Aml)

THOMSON REUTERS

Cero Therapeutics treatment of leukemia granted orphan designation

Cero Therapeutics Receives Nasdaq Delisting Notice Due to Bid Price Non-Compliance; Implements Reverse Stock Split to Address Issue

CERo Therapeutics Holdings Inc trading halted, news pending

Cero Therapeutics Announces 1-for-20 Reverse Stock Split Effective June 13, 2025

Cero Therapeutics Holdings, Inc. Announces Reverse Stock Split

THOMSON REUTERS

Cero Therapeutics Holdings Inc - Announces One-for-Twenty Reverse Stock Split

THOMSON REUTERS

Cero Therapeutics Holdings Inc. Announces Exercise of Option for Additional Series D Financing to Support Clinical Advancements

Cero Therapeutics, Inc. Announces Option Exercise for Additional Series D Financing

THOMSON REUTERS

Cero Therapeutics Holdings Inc. Appoints Chris Ehrlich as New CEO with Revised Employment Agreement

Cero Therapeutics Holdings Inc. Expands IP Portfolio with New U.S. and European Patent Approvals for Lead Compound CER-1236

BRIEF-CERo Therapeutics Holdings, Inc. Doses First Patient with CER-1236 in Phase 1 Clinical Trial

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/CERO/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"CERO","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CERO\",,,,,undefined,":{"symbol":"CERO","market":"US","secType":"STK","nameCN":"CERo Therapeutics Holdings, Inc.","latestPrice":9.46,"timestamp":1751486400000,"preClose":9.23,"halted":0,"volume":90891,"hourTrading":{"tag":"盘后","latestPrice":9.36,"preClose":9.46,"latestTime":"19:59 EDT","volume":310,"amount":2892.8625,"timestamp":1751500790017},"delay":0,"floatShares":317500,"shares":516100,"eps":-11135.544,"marketStatus":"Closed","change":0.23,"latestTime":"07-02 16:00:00 EDT","open":9.1,"high":9.73,"low":9.1,"amount":858134.4699779999,"amplitude":0.068256,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-11135.544,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1751529600000},"marketStatusCode":5,"adr":0,"exchange":"NASDAQ","adjPreClose":9.23,"preHourTrading":{"tag":"盘前","latestPrice":9.15,"preClose":9.23,"latestTime":"09:26 EDT","volume":1390,"amount":12688.462099999999,"timestamp":1751462764147},"postHourTrading":{"tag":"盘后","latestPrice":9.36,"preClose":9.46,"latestTime":"19:59 EDT","volume":310,"amount":2892.8625,"timestamp":1751500790017},"volumeRatio":0.384305},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CERO\",,,,,undefined,":{"symbol":"CERO","floatShares":317500,"roa":"-122.86%","roe":"--","lyrEps":-15538.9768,"volumeRatio":0.384305,"shares":516100,"dividePrice":0,"high":9.73,"amplitude":0.068256,"preClose":9.23,"low":9.1,"week52Low":6.71,"pbRate":"-1.77","week52High":895.4,"institutionHeld":0,"latestPrice":9.46,"eps":-11135.544,"divideRate":0,"volume":90891,"delay":0,"ttmEps":-11135.544,"open":9.1,"prevYearClose":120,"prevWeekClose":9.55,"prevMonthClose":9.63,"prevQuarterClose":9.63,"fiveDayClose":11.19,"twentyDayClose":9.38,"sixtyDayClose":14.302},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"CERO\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2548487950","title":"Cero Therapeutics Holdings Inc. Completes Additional Closings, Issuing 938 and 2,315 Shares of Series D Preferred Stock for $750,400 and $1,852,000 Respectively","url":"https://stock-news.laohu8.com/highlight/detail?id=2548487950","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2548487950?lang=en_us&edition=fundamental","pubTime":"2025-07-01 05:10","pubTimestamp":1751317809,"startTime":"0","endTime":"0","summary":"Cero Therapeutics Holdings Inc. Completes Additional Closings, Issuing 938 and 2,315 Shares of Series D Preferred Stock for $750,400 and $1,852,000 Respectively. Cero Therapeutics Holdings Inc. recently amended its securities purchase agreement, adding new institutional investors to issue and sell shares of its Series D convertible preferred stock. On June 25, 2025, the company completed an Additional Closing, selling 2,315 shares for approximately $1,852,000. Previously, on June 5, 2025, the company sold an additional 938 shares for about $750,400. The transactions were conducted under exemptions from the Securities Act for private placements to accredited investors.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cero Therapeutics Hol","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250630:nNDL36Rp1r:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CERO"],"gpt_icon":0},{"id":"2545443735","title":"CERo Therapeutics Raised to Buy From Hold by D. Boral Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2545443735","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2545443735?lang=en_us&edition=fundamental","pubTime":"2025-06-23 23:16","pubTimestamp":1750691760,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/CERO/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  June 23, 2025 11:16 ET (15:16 GMT)","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CERO","LENZ"],"gpt_icon":0},{"id":"2545411954","title":"Cero Therapeutics Announces No Dose-Limiting Toxicities in First Patient of Phase 1 Trial for Novel Cancer Therapy CER-1236","url":"https://stock-news.laohu8.com/highlight/detail?id=2545411954","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2545411954?lang=en_us&edition=fundamental","pubTime":"2025-06-23 20:15","pubTimestamp":1750680917,"startTime":"0","endTime":"0","summary":"SOUTH SAN FRANCISCO, Calif., June 23, 2025 - CERo Therapeutics Holdings, Inc.  announced the completion of the initial evaluation of the first patient in its Phase 1 clinical trial of its lead compound, CER-1236. The trial, titled \"Phase 1/1b First-in-human Study of Autologous Chimeric Engulfment Receptor T-Cell CER-1236 in Patients With Acute Myeloid Leukemia ,\" is designed to assess the safety and preliminary efficacy of CER-1236 in patients with acute myeloid leukemia. Preliminary results from the trial's Dose Escalation Safety Committee indicate that the first patient demonstrated no dose-limiting toxicity during the 28-day observation period. The company plans to dose a second patient in the cohort shortly. CERo has announced plans to initiate a second trial of CER-1236 in solid tumors later this year. Further updates on the trial's progress will be provided in the future.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250623:nNDLSRJnp:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B3QW5Z07.USD","LU2095319765.USD","CERO","IE00BKPKM429.USD","IE00B64PRP62.GBP","BK4585","IE00BGHQF748.EUR","LU2210150020.SGD","BK4139","LU2210149790.SGD","NDAQ","BK4112","BK4588"],"gpt_icon":1},{"id":"2545116364","title":"Cero Therapeutics Holdings, Inc. Announces First Patient Completes Dose-Limiting Toxicity Observation Period With No Reported Dlts in Phase 1 Trial of Cer-1236","url":"https://stock-news.laohu8.com/highlight/detail?id=2545116364","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2545116364?lang=en_us&edition=fundamental","pubTime":"2025-06-23 20:15","pubTimestamp":1750680900,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250623:nTUA52QVXR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CERO","BK4139"],"gpt_icon":0},{"id":"2544974589","title":"Top Premarket Decliners","url":"https://stock-news.laohu8.com/highlight/detail?id=2544974589","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2544974589?lang=en_us&edition=fundamental","pubTime":"2025-06-18 19:45","pubTimestamp":1750247114,"startTime":"0","endTime":"0","summary":"CERo Therapeutics  shares were 27% lower pre-bell Wednesday, paring Tuesday's rally.Borealis Foods  stock was down 22% following a 6.6% increase in the previous session.Eyenovia  shares were 16% lower, shaving gains from the previous session.Regencell Bioscience  stock was down 12% after a 30% increase on Tuesday.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["CERO","BRLS","BK4007","EYEN","BK4539","BK4212","BK4139"],"gpt_icon":0},{"id":"2544399294","title":"Top Midday Gainers","url":"https://stock-news.laohu8.com/highlight/detail?id=2544399294","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2544399294?lang=en_us&edition=fundamental","pubTime":"2025-06-18 02:14","pubTimestamp":1750184079,"startTime":"0","endTime":"0","summary":"CERo Therapeutics  said Tuesday that the US Food and Drug Administration has granted orphan drug designation for its lead drug candidate, CER-1236, for acute myeloid leukemia.Shares jumped over 220% as intraday trading volume advanced to over 51.2 million from a daily average of about 101,000.Acurx Pharmaceuticals  said its lead antibiotic candidate, ibezapolstat, is ready to advance to international phase 3 clinical trials to treat patients with C. difficile infection.Shares soared over 130% as intraday trading volume surged to more than 309 million from a daily average of roughly 182,000.Eli Lilly  said that it agreed to acquire Verve Therapeutics  for up to about $1.3 billion to advance gene-editing therapies for cardiovascular disease.Verve shares soared 78%, with intraday trading volume of more than 72.5 million against a daily average of about 3.49 million.Price: 22.04, Change: +15.18, Percent Change: +220.97","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU0456855351.SGD","LU2361045086.USD","BK4007","BK4588","LU0234572021.USD","LU2468319806.SGD","LU1366192091.USD","SG9999015945.SGD","LU0061475181.USD","SG9999018857.SGD","LU0385154629.USD","LU2112291526.USD","LU0106261372.USD","LU0354030438.USD","LU0320765059.SGD","SGXZ81514606.USD","LU0097036916.USD","LU0820561818.USD","LU2602419157.SGD","LU1093756168.USD","SGXZ51526630.SGD","LU2237443978.SGD","LU0471298777.SGD","LU0320765992.SGD","IE0009355771.USD","LU0417517546.SGD","BK4516","GB00BDT5M118.USD","LU1023059063.AUD","LU2491050154.USD","LU2552382215.SGD","BK4563","LU1917777945.USD","LU2237438978.USD","SG9999014906.USD","IE00BK4W5L77.USD","CERO","LU1974910355.USD","LU1720051108.HKD","LU0354030511.USD","LU1232071149.USD","LU0889565916.HKD","LU0058720904.USD","ACXP","SG9999015986.USD","IE00BJT1NW94.SGD","LU1291159041.SGD","LU0786609619.USD"],"gpt_icon":1},{"id":"2544944993","title":"CERo Therapeutics Holdings Inc trading halted, volatility trading pause","url":"https://stock-news.laohu8.com/highlight/detail?id=2544944993","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2544944993?lang=en_us&edition=fundamental","pubTime":"2025-06-17 21:50","pubTimestamp":1750168251,"startTime":"0","endTime":"0","summary":"09:46 EDT CERo Therapeutics (CERO) Holdings Inc trading halted, volatility trading pause Published first on TheFly – the ultimate source for real-t...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/cero-therapeutics-holdings-inc-trading-halted-volatility-trading-pause-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/cero-therapeutics-holdings-inc-trading-halted-volatility-trading-pause-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LENZ","BK4007","BK4539","BK4139","CERO"],"gpt_icon":0},{"id":"2544962193","title":"Cero Therapeutics Holdings Inc. Receives FDA Orphan Drug Designation for CER-1236 in Acute Myeloid Leukemia Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2544962193","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2544962193?lang=en_us&edition=fundamental","pubTime":"2025-06-17 20:15","pubTimestamp":1750162513,"startTime":"0","endTime":"0","summary":"Cero Therapeutics Holdings Inc.  announced that the U.S. Food and Drug Administration  has granted Orphan Drug Designation  to its lead drug candidate, CER-1236, for the treatment of acute myeloid leukemia . This designation highlights the significance of developing innovative treatments for conditions affecting fewer than 200,000 patients in the U.S. annually. CER-1236, currently in Phase 1 clinical trials, utilizes engineered T cell therapeutics that incorporate phagocytic mechanisms. The ODD status provides Cero with several incentives, including FDA assistance in trial design, access to the FDA Orphan Drug Grants Program, exemption from the drug approval application fee, and eligibility for seven years of marketing exclusivity.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250617:nNDL8zmcwF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BGHQF748.EUR","BK4139","LU2210149790.SGD","BK4588","IE00B3QW5Z07.USD","NDAQ","BK4585","IE00BKPKM429.USD","CERO","BK4112","LU2210150020.SGD","IE00B64PRP62.GBP","LU2095319765.USD"],"gpt_icon":0},{"id":"2544962980","title":"Cero Therapeutics Holdings, Inc. Announces FDA Orphan Drug Designation Granted to Cer-1236 for the Treatment of Acute Myeloid Leukemia (Aml)","url":"https://stock-news.laohu8.com/highlight/detail?id=2544962980","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2544962980?lang=en_us&edition=fundamental","pubTime":"2025-06-17 20:15","pubTimestamp":1750162500,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250617:nTUA3NCSPY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CERO","BK4139"],"gpt_icon":0},{"id":"2544057985","title":"Cero Therapeutics treatment of leukemia granted orphan designation","url":"https://stock-news.laohu8.com/highlight/detail?id=2544057985","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2544057985?lang=en_us&edition=fundamental","pubTime":"2025-06-17 06:00","pubTimestamp":1750111207,"startTime":"0","endTime":"0","summary":"The FDA granted orphan designation to a treatment of acute myeloid leukemia being developed by Cero Therapeutics (CERO), according to a post to the...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/cero-therapeutics-treatment-of-leukemia-granted-orphan-designation-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/cero-therapeutics-treatment-of-leukemia-granted-orphan-designation-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CERO","LENZ","BK4007","BK4139","BK4539"],"gpt_icon":0},{"id":"2543589456","title":"Cero Therapeutics Receives Nasdaq Delisting Notice Due to Bid Price Non-Compliance; Implements Reverse Stock Split to Address Issue","url":"https://stock-news.laohu8.com/highlight/detail?id=2543589456","media":"Reuters","labels":["shareholding","policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2543589456?lang=en_us&edition=fundamental","pubTime":"2025-06-14 05:14","pubTimestamp":1749849295,"startTime":"0","endTime":"0","summary":"Cero Therapeutics Receives Nasdaq Delisting Notice Due to Bid Price Non-Compliance; Implements Reverse Stock Split to Address Issue. Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cero Therapeutics Holdings Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 13, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250613:nNDL3J2T2m:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"shareholding,policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CERO","BK4139"],"gpt_icon":0},{"id":"2543525490","title":"CERo Therapeutics Holdings Inc trading halted, news pending","url":"https://stock-news.laohu8.com/highlight/detail?id=2543525490","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2543525490?lang=en_us&edition=fundamental","pubTime":"2025-06-13 07:50","pubTimestamp":1749772209,"startTime":"0","endTime":"0","summary":"19:50 EDT CERo Therapeutics (CERO) Holdings Inc trading halted, news pending Published first on TheFly – the ultimate source for real-time, market-...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/cero-therapeutics-holdings-inc-trading-halted-news-pending-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/cero-therapeutics-holdings-inc-trading-halted-news-pending-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LENZ","BK4539","BK4139","CERO","BK4007"],"gpt_icon":0},{"id":"2542658278","title":"Cero Therapeutics Announces 1-for-20 Reverse Stock Split Effective June 13, 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2542658278","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2542658278?lang=en_us&edition=fundamental","pubTime":"2025-06-11 21:10","pubTimestamp":1749647408,"startTime":"0","endTime":"0","summary":"Cero Therapeutics Holdings Inc.  announced a one-for-twenty reverse stock split of its common stock, effective June 13, 2025. As a result, the number of outstanding shares will be reduced from approximately 10.3 million to about 516,092. The stock will trade on a split-adjusted basis on the Nasdaq Capital Market. Proportional adjustments will also be made to equity incentive plans, stock options, preferred stock, and warrants.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cero Therapeutics Holdings Inc. published the original content used to generate this news brief via GlobeNewswire  on June 11, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250611:nNDL7lbSgH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BK4112","IE00B3QW5Z07.USD","LU2095319765.USD","IE00B64PRP62.GBP","NDAQ","BK4139","CERO","IE00BGHQF748.EUR","IE00BKPKM429.USD","LU2210149790.SGD","LU2210150020.SGD","BK4588"],"gpt_icon":0},{"id":"2542582223","title":"Cero Therapeutics Holdings, Inc. Announces Reverse Stock Split","url":"https://stock-news.laohu8.com/highlight/detail?id=2542582223","media":"THOMSON REUTERS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2542582223?lang=en_us&edition=fundamental","pubTime":"2025-06-11 21:10","pubTimestamp":1749647400,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250611:nTUA6RS1HC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","CERO"],"gpt_icon":0},{"id":"2542225582","title":"Cero Therapeutics Holdings Inc - Announces One-for-Twenty Reverse Stock Split","url":"https://stock-news.laohu8.com/highlight/detail?id=2542225582","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2542225582?lang=en_us&edition=fundamental","pubTime":"2025-06-11 21:10","pubTimestamp":1749647400,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250611:nTUA6RS1HC:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CERO","BK4139"],"gpt_icon":0},{"id":"2541361857","title":"Cero Therapeutics Holdings Inc. Announces Exercise of Option for Additional Series D Financing to Support Clinical Advancements","url":"https://stock-news.laohu8.com/highlight/detail?id=2541361857","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2541361857?lang=en_us&edition=fundamental","pubTime":"2025-06-06 20:15","pubTimestamp":1749212114,"startTime":"0","endTime":"0","summary":"Cero Therapeutics Holdings Inc. Announces Exercise of Option for Additional Series D Financing to Support Clinical Advancements. Cero Therapeutics Holdings Inc. has announced the exercise of an option for additional Series D financing. The company issued more shares of its Series D Preferred Stock to institutional investors, generating approximately $750,000 in gross proceeds. This funding will support the advancement of their clinical programs, including the recent FDA IND allowances in liquid and solid tumors.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cero Therapeutics Holdings Inc. published the original content used to generate this news brief via GlobeNewswire  on June 06, 2025, and is solely responsible for the information c","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250606:nNDL6DMj0v:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B3QW5Z07.USD","LU2095319765.USD","LU2210149790.SGD","IE00B64PRP62.GBP","NDAQ","BK4139","CERO","IE00BKPKM429.USD","IE00BGHQF748.EUR","BK4585","BK4112","LU2210150020.SGD","BK4588"],"gpt_icon":0},{"id":"2541573318","title":"Cero Therapeutics, Inc. Announces Option Exercise for Additional Series D Financing","url":"https://stock-news.laohu8.com/highlight/detail?id=2541573318","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2541573318?lang=en_us&edition=fundamental","pubTime":"2025-06-06 20:15","pubTimestamp":1749212100,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250606:nTUA8P4TMK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CERO","BK4139"],"gpt_icon":0},{"id":"2540713988","title":"Cero Therapeutics Holdings Inc. Appoints Chris Ehrlich as New CEO with Revised Employment Agreement","url":"https://stock-news.laohu8.com/highlight/detail?id=2540713988","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540713988?lang=en_us&edition=fundamental","pubTime":"2025-06-03 04:22","pubTimestamp":1748895760,"startTime":"0","endTime":"0","summary":"Cero Therapeutics Holdings Inc. has announced a management change, appointing Chris Ehrlich as the new Chief Executive Officer effective June 4, 2025. This appointment follows the termination of his previous consulting agreement, expanding his role to a full-time position with the company. Ehrlich's leadership will be integral as Cero Therapeutics moves forward.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cero Therapeutics Holdings Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 02, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250602:nNDLc1hcH4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CERO"],"gpt_icon":0},{"id":"2540479342","title":"Cero Therapeutics Holdings Inc. Expands IP Portfolio with New U.S. and European Patent Approvals for Lead Compound CER-1236","url":"https://stock-news.laohu8.com/highlight/detail?id=2540479342","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540479342?lang=en_us&edition=fundamental","pubTime":"2025-06-02 21:05","pubTimestamp":1748869517,"startTime":"0","endTime":"0","summary":"Cero Therapeutics Holdings Inc. has announced a significant expansion of its intellectual property portfolio with the granting of two U.S. patents and the allowance of a European patent application. These developments pertain to the company's lead compound, CER-1236, and contribute to a total of 18 issued patents and allowed applications internationally, encompassing nine patent families. The newly granted U.S. Patent No. 12,303,551, titled \"CELLULAR IMMUNOTHERAPY COMPOSITIONS AND USES THEREOF,\" covers combination therapies involving CER-1236 for cancer treatment. The company's intellectual property now has protection extending to 2042 in the United States.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cero Therapeutics Holdings Inc. ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250602:nNDL8L8lVs:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2210150020.SGD","LU2095319765.USD","LU2210149790.SGD","BK4112","IE00BGHQF748.EUR","NDAQ","BK4588","IE00B64PRP62.GBP","BK4139","CERO","IE00B3QW5Z07.USD","BK4585","IE00BKPKM429.USD"],"gpt_icon":0},{"id":"2539422755","title":"BRIEF-CERo Therapeutics Holdings, Inc. Doses First Patient with CER-1236 in Phase 1 Clinical Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2539422755","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2539422755?lang=en_us&edition=fundamental","pubTime":"2025-05-30 20:52","pubTimestamp":1748609544,"startTime":"0","endTime":"0","summary":"BRIEF-CERo Therapeutics Holdings, Inc. Doses First Patient with CER-1236 in Phase 1 Clinical TrialMay 30 (Reuters) - CERo Therapeutics Holdings Inc CERO.O:CERO THERAPEUTICS HOLDINGS, INC. DOSES FIRST ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250530:nTUA3KVDL3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CERO"],"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":1,"totalSize":60,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/CERO\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-06-13","symbol":"CERO","defaultRemindTime":1749821400000,"type":"split","dateTimestamp":1749787200000,"forFactor":20,"toFactor":1,"ratio":20},{"market":"US","date":"2025-01-08","symbol":"CERO","defaultRemindTime":1736346600000,"type":"split","dateTimestamp":1736312400000,"forFactor":100,"toFactor":1,"ratio":100},{"market":"US","date":"2024-02-15","symbol":"CERO","reason":null,"defaultRemindTime":1708007400000,"announcedDate":"2024-02-14","type":"delisting","dateTimestamp":1707973200000}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"CERO\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"CERO\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":1,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":1,"analysts":2,"updateTime":1750737600000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/CERO\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"CERO","date":"2025-07-01","current":-0.334649,"percent":0.857585,"low":-23.40166,"twenty":-6.816356,"median":-1.733515,"eighty":-0.475509,"high":-0.137942,"avg":-3.931905,"sd":4.868416,"marketCap":3718171},"quantilePoints":[{"date":"2024-02-23","current":-14.247617,"twenty":-20.956561,"median":-17.613942,"eighty":-14.944588,"marketCap":35849112},{"date":"2024-03-01","current":-17.506812,"twenty":-18.431546,"median":-15.409236,"eighty":-15.153206,"marketCap":44049729},{"date":"2024-03-08","current":-18.247371,"twenty":-17.820809,"median":-15.409236,"eighty":-15.203159,"marketCap":45913085},{"date":"2024-03-15","current":-13.270815,"twenty":-17.820809,"median":-15.409236,"eighty":-15.057448,"marketCap":33391335},{"date":"2024-03-22","current":-12.856102,"twenty":-17.518661,"median":-15.34438,"eighty":-13.839564,"marketCap":32347855},{"date":"2024-03-28","current":-9.656887,"twenty":-17.423869,"median":-15.187199,"eighty":-12.785008,"marketCap":24298158},{"date":"2024-04-05","current":-11.26226,"twenty":-17.423869,"median":-15.107401,"eighty":-12.559878,"marketCap":28563716},{"date":"2024-04-12","current":-10.85589,"twenty":-17.252059,"median":-14.262796,"eighty":-11.529063,"marketCap":27533066},{"date":"2024-04-19","current":-8.940145,"twenty":-16.820909,"median":-13.270815,"eighty":-10.646899,"marketCap":22674290},{"date":"2024-04-26","current":-8.185457,"twenty":-16.072132,"median":-12.878911,"eighty":-10.171589,"marketCap":20760226},{"date":"2024-05-03","current":-8.011298,"twenty":-15.61915,"median":-12.441389,"eighty":-9.218799,"marketCap":20318519},{"date":"2024-05-10","current":-6.676082,"twenty":-15.409236,"median":-11.944081,"eighty":-8.208678,"marketCap":16932099},{"date":"2024-05-17","current":-6.559976,"twenty":-15.406992,"median":-11.26226,"eighty":-8.011298,"marketCap":16637628},{"date":"2024-05-24","current":-5.773123,"twenty":-15.356229,"median":-10.681731,"eighty":-7.83714,"marketCap":13841623},{"date":"2024-05-31","current":-6.030941,"twenty":-15.281507,"median":-10.409864,"eighty":-6.954736,"marketCap":14459767},{"date":"2024-06-07","current":-4.748738,"twenty":-15.235078,"median":-10.159255,"eighty":-6.68061,"marketCap":11385560},{"date":"2024-06-14","current":-2.25909,"twenty":-15.107401,"median":-9.656887,"eighty":-6.509425,"marketCap":5416387},{"date":"2024-06-21","current":-1.821847,"twenty":-15.007495,"median":-8.940145,"eighty":-6.069835,"marketCap":4368054},{"date":"2024-06-28","current":-1.912311,"twenty":-14.84161,"median":-8.707933,"eighty":-5.984352,"marketCap":4584951},{"date":"2024-07-05","current":-1.595686,"twenty":-14.277975,"median":-8.24351,"eighty":-5.773123,"marketCap":3825813},{"date":"2024-07-12","current":-1.228176,"twenty":-14.247617,"median":-8.069351,"eighty":-4.748738,"marketCap":2944671},{"date":"2024-07-15","current":-1.226291,"twenty":-14.24184,"median":-8.069351,"eighty":-4.719086,"marketCap":2940152},{"date":"2024-08-02","current":-1.013952,"twenty":-14.236062,"median":-8.040325,"eighty":-4.535268,"marketCap":2431048},{"date":"2024-08-09","current":-0.885794,"twenty":-13.839564,"median":-8.011298,"eighty":-2.310102,"marketCap":2123778},{"date":"2024-08-16","current":-0.654013,"twenty":-13.158247,"median":-7.83714,"eighty":-1.891957,"marketCap":2229214},{"date":"2024-08-23","current":-2.636712,"twenty":-12.954324,"median":-7.140505,"eighty":-1.844463,"marketCap":7260829},{"date":"2024-08-30","current":-2.420589,"twenty":-12.883473,"median":-6.744599,"eighty":-1.891957,"marketCap":6665683},{"date":"2024-09-06","current":-2.068131,"twenty":-12.832404,"median":-6.687402,"eighty":-1.924373,"marketCap":5695102},{"date":"2024-09-13","current":-1.60378,"twenty":-12.678367,"median":-6.559976,"eighty":-1.829704,"marketCap":4416400},{"date":"2024-09-20","current":-1.622429,"twenty":-12.393993,"median":-6.417311,"eighty":-1.725453,"marketCap":4467754},{"date":"2024-09-27","current":-1.758564,"twenty":-12.190139,"median":-6.030941,"eighty":-1.729099,"marketCap":4842634},{"date":"2024-10-04","current":-1.723131,"twenty":-12.057464,"median":-5.826769,"eighty":-1.723525,"marketCap":4745063},{"date":"2024-10-11","current":-1.770191,"twenty":-11.67976,"median":-5.685419,"eighty":-1.725453,"marketCap":4874653},{"date":"2024-10-18","current":-1.640939,"twenty":-11.355145,"median":-5.192459,"eighty":-1.725453,"marketCap":4518726},{"date":"2024-10-25","current":-4.541316,"twenty":-11.227428,"median":-4.704227,"eighty":-1.717164,"marketCap":12505622},{"date":"2024-10-31","current":-4.448525,"twenty":-11.088102,"median":-4.448525,"eighty":-1.723131,"marketCap":12250098},{"date":"2024-11-08","current":-3.853568,"twenty":-10.85589,"median":-4.424907,"eighty":-1.725101,"marketCap":10611741},{"date":"2024-11-15","current":-10.217961,"twenty":-11.088102,"median":-4.448525,"eighty":-1.726861,"marketCap":28137649},{"date":"2024-11-22","current":-5.605162,"twenty":-11.378366,"median":-4.622772,"eighty":-1.72898,"marketCap":37261342},{"date":"2024-11-29","current":-5.285991,"twenty":-11.285481,"median":-4.70795,"eighty":-1.736236,"marketCap":29010326},{"date":"2024-12-06","current":-5.244908,"twenty":-11.122934,"median":-4.743697,"eighty":-1.739542,"marketCap":28784857},{"date":"2024-12-13","current":-1.906243,"twenty":-10.902332,"median":-4.70795,"eighty":-1.744391,"marketCap":10461755},{"date":"2024-12-20","current":-1.478982,"twenty":-10.729812,"median":-4.535858,"eighty":-1.726509,"marketCap":8116878},{"date":"2024-12-27","current":-2.097767,"twenty":-10.58386,"median":-4.43215,"eighty":-1.724313,"marketCap":11512866},{"date":"2025-01-03","current":-2.13273,"twenty":-10.499069,"median":-4.417664,"eighty":-1.725805,"marketCap":11704747},{"date":"2025-01-10","current":-1.293623,"twenty":-10.455734,"median":-4.2029,"eighty":-1.723525,"marketCap":7099600},{"date":"2025-01-17","current":-0.870573,"twenty":-10.310323,"median":-4.062655,"eighty":-1.649339,"marketCap":4777839},{"date":"2025-01-24","current":-0.821625,"twenty":-10.217961,"median":-3.965464,"eighty":-1.627827,"marketCap":4509205},{"date":"2025-01-31","current":-0.695759,"twenty":-10.19009,"median":-3.820818,"eighty":-1.596315,"marketCap":3818433},{"date":"2025-02-07","current":-0.713241,"twenty":-10.159255,"median":-2.907717,"eighty":-1.573503,"marketCap":3914374},{"date":"2025-02-14","current":-0.62933,"twenty":-10.101202,"median":-2.636712,"eighty":-1.510537,"marketCap":3453859},{"date":"2025-02-21","current":-0.716737,"twenty":-9.74575,"median":-2.540899,"eighty":-1.377788,"marketCap":3933562},{"date":"2025-02-28","current":-0.562901,"twenty":-9.640801,"median":-2.437302,"eighty":-1.224909,"marketCap":3089285},{"date":"2025-03-07","current":-0.510457,"twenty":-9.079472,"median":-2.372103,"eighty":-1.030709,"marketCap":2801464},{"date":"2025-03-14","current":-0.335713,"twenty":-8.754375,"median":-2.239137,"eighty":-0.96912,"marketCap":1842442},{"date":"2025-03-21","current":-0.335643,"twenty":-8.503123,"median":-2.198781,"eighty":-0.896348,"marketCap":1842058},{"date":"2025-03-28","current":-0.267465,"twenty":-8.285192,"median":-2.14239,"eighty":-0.857987,"marketCap":1467890},{"date":"2025-04-04","current":-0.24439,"twenty":-8.197068,"median":-2.097767,"eighty":-0.804927,"marketCap":1341248},{"date":"2025-04-11","current":-0.269213,"twenty":-8.092572,"median":-2.074831,"eighty":-0.719534,"marketCap":1477484},{"date":"2025-04-17","current":-0.137942,"twenty":-8.069351,"median":-2.037496,"eighty":-0.697857,"marketCap":1145530},{"date":"2025-04-25","current":-0.719207,"twenty":-8.034519,"median":-1.993365,"eighty":-0.682473,"marketCap":5972602},{"date":"2025-05-02","current":-0.577828,"twenty":-8.011298,"median":-1.936658,"eighty":-0.655985,"marketCap":4798528},{"date":"2025-05-09","current":-0.472927,"twenty":-8.011298,"median":-1.906243,"eighty":-0.642767,"marketCap":3927389},{"date":"2025-05-16","current":-0.378199,"twenty":-7.976467,"median":-1.862996,"eighty":-0.625834,"marketCap":3140728},{"date":"2025-05-23","current":-0.254249,"twenty":-7.883582,"median":-1.835754,"eighty":-0.593155,"marketCap":2824879},{"date":"2025-05-30","current":-0.250375,"twenty":-7.83714,"median":-1.821847,"eighty":-0.577167,"marketCap":2781833},{"date":"2025-06-06","current":-0.207274,"twenty":-7.721034,"median":-1.77581,"eighty":-0.547912,"marketCap":2302949},{"date":"2025-06-13","current":-0.273488,"twenty":-7.384327,"median":-1.751459,"eighty":-0.512702,"marketCap":3038630},{"date":"2025-06-20","current":-0.399633,"twenty":-7.094063,"median":-1.745839,"eighty":-0.507659,"marketCap":4440184},{"date":"2025-06-27","current":-0.371137,"twenty":-6.877648,"median":-1.738983,"eighty":-0.492098,"marketCap":4123580},{"date":"2025-07-01","current":-0.334649,"twenty":-6.816356,"median":-1.733515,"eighty":-0.475509,"marketCap":3718171}],"updateTime":1751515050684}}}